BMJ Open (Feb 2021)

Diagnostic and prognostic factors in patients with prostate cancer: a systematic review protocol

  • Antonella Cardone,
  • Nicolas Mottet,
  • Lisa Moris,
  • Michael Lardas,
  • Anna Haire,
  • Francesco Barletta,
  • Simone Scuderi,
  • Eleni Vradi,
  • Giorgio Gandaglia,
  • Steven MacLennan,
  • Bahman Farahmand,
  • Sara J Maclennan,
  • Zsuzsanna Devecseri,
  • Alex Asiimwe,
  • Laurence Collette,
  • Anders Bjartell,
  • James Ndow,
  • James N'Dow,
  • Karin Plass,
  • Maria Ribal,
  • Thomas Van den Broeck,
  • Peter-Paul Willemse,
  • Karl H Pang,
  • Riccardo Campi,
  • Isabella Greco,
  • Mauro Gacci,
  • Sergio Serni,
  • Susan Evans-Axelsson,
  • Ragnar Lonnerbro,
  • Daniele Crosti,
  • Massimiliano Meoni,
  • Roberto Garzonio,
  • Chris Bangma,
  • Monique Roobol,
  • Sebastiaan Remmers,
  • Derya Tilki,
  • Teemu Murtola,
  • Tapio Visakorpi,
  • Kirsi Talala,
  • Teuvo Tammela,
  • Aino Siltari,
  • Stephane Lejeune,
  • Femke van Diggelen,
  • Georgia Taxiarchopoulou,
  • Ketharini Senthilkumar,
  • Stefanie Schütte,
  • Sophie Byrne,
  • Luz Fialho,
  • Paulina Gono,
  • Monica De Vetter,
  • Klevisa Ceke,
  • Bertrand De Meulder,
  • Charles Auffray,
  • Irina-Afrodita Balaur,
  • Nesrine Taibi,
  • Shaun Power,
  • Nazanin Zounemat Kermani,
  • Kees van Bochove,
  • Marinel Cavelaars,
  • Maxim Moinat,
  • Emma Voss,
  • Chiara Bernini,
  • Denis Horgan,
  • Louise Fullwood,
  • Marc Holtorf,
  • Doron Lancet,
  • Gabi Bernstein,
  • Imran Omar,
  • Sara MacLennan,
  • Jemma Healey,
  • Johannes Huber,
  • Manfred Wirth,
  • Michael Froehner,
  • Beate Brenner,
  • Angelika Borkowetz,
  • Christian Thomas,
  • Friedemann Horn,
  • Kristin Reiche,
  • Markus Kreuz,
  • Andreas Josefsson,
  • Delila Gasi Tandefelt,
  • Jonas Hugosson,
  • Jack Schalken,
  • Henkjan Huisman,
  • Thomas Hofmarcher,
  • Emelie Andersson,
  • Adam Fridhammar,
  • Frank Verholen,
  • John-Edward Butler-Ransohoff,
  • Todd Williamson,
  • Kumari Chandrawansa,
  • Dorothy Dlamini,
  • Reg Waldeck,
  • Megan Molnar,
  • Amanda Bruno,
  • Ronald Herrera,
  • Ekaterina Nevedomskaya,
  • Niculae Constantinovici,
  • Carl Steinbeißer,
  • Sini Thomas,
  • Monika Maass,
  • Patrizia Torremante,
  • Marc Dietrich Voss,
  • Guido Cuperus,
  • Chad Dau Kishore,
  • Papineni Jing,
  • Wang-silvanto Steve,
  • Hass Robert,
  • Snijder Verena,
  • Doyé Xuewei,
  • Wang Andy Garnham,
  • Mark Lambrecht,
  • Russ Wolfinger,
  • Stijn Rogiers,
  • Angela Servan,
  • Florence Lefresne,
  • Joaquin Casariego,
  • Mohamed Samir,
  • Joe Lawson,
  • Katie Pascoe,
  • Bertrand Jaton,
  • Daniel Bakkard,
  • Heidi Turunen,
  • Olavi Kilkku,
  • Pasi Pohjanjousi,
  • Olli Voima,
  • Liina Nevalaita,
  • Sonia Araujo,
  • Elaine Longden-Chapman,
  • Gordon McVie,
  • Danny Burke,
  • Paul Agapow,
  • Sahra Derkits,
  • Muriel Licour,
  • Charles McCrea,
  • Sarah Payne,
  • Alan Yong,
  • Flavia Lujan,
  • Billy Franks,
  • Michael Bussmann,
  • Inken Köhle

DOI
https://doi.org/10.1136/bmjopen-2020-040531
Journal volume & issue
Vol. 11, no. 2

Abstract

Read online

Introduction As part of the PIONEER (Prostate Cancer Diagnosis and Treatment Enhancement Through the Power of Big Data in Europe) Consortium, we will explore which diagnostic and prognostic factors (DPFs) are currently being researched to previously defined clinical and patient-reported outcomes for prostate cancer (PCa).Methods and analysis This research project will follow the following four steps: (1) a broad systematic literature review of DPFs for all stages of PCa, covering evidence from 2014 onwards; (2) discussion of systematic review findings by a multidisciplinary expert panel; (3) risk of bias assessment and applicability with Prediction model Risk Of Bias Assessment Tool criteria, Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) and the Quality In Prognosis Studies tool (QUIPS) and (4) additional quantitative assessments if required.Ethics and dissemination We aim to develop an online tool to present the DPFs identified in this research and make them available across all stakeholders. There are no ethical implications.